Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer

Inclusion Criteria: * Must be ≥ 18 years of age * Ability to understand and the willingness to sign a written informed consent document. Patient must sign the informed consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Participants must have histologically confirmed advanced (International Federation of Gynecology and Obstetrics \[FIGO\] stage III or IV), persistent, or recurrent endometrial cancer (histologic documentation of recurrence not required) that has * Patient's archival endometrial cancer tumor specimen has positive hormone receptor expression defined as "positive" or ≥ 1% by immunohistochemistry (IHC) performed at any Clinical Laboratory Improvement Act (CLIA)-certified laboratory * Can be any histologic subtype including endometrioid, mixed, serous, clear cell, carcinosarcoma * Prior treatment with at least one line of platinum-based chemotherapy is required (can be in the adjuvant setting): * Patients with mismatch repair deficiency (dMMR) tumors must have received at least one prior line of immunotherapy. An exception may be made for patients with documented contraindications to immunotherapy, including but not limited to severe autoimmune conditions, solid organ transplantation, or lack of access to immunotherapy. * Prior exposure to to progestins, aromatase inhibitors, tamoxifen, selective estrogen receptor down regu…